Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 5,833 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $29.64, for a total value of $172,890.12. Following the completion of the sale, the chief executive officer directly owned 567,913 shares in the company, valued at $16,832,941.32. This represents a 1.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Abraham Ceesay also recently made the following trade(s):

• On Wednesday, December 17th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The stock was sold at an average price of $29.63, for a total value of $150,609.29.
• On Monday, November 17th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The shares were sold at an average price of $25.20, for a total value of $128,091.60.
• On Monday, November 17th, Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock. The shares were sold at an average price of $25.19, for a total value of $146,933.27.
• On Wednesday, October 15th, Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock. The stock was sold at an average price of $25.81, for a total value of $131,192.23.
• On Wednesday, October 15th, Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock. The stock was sold at an average price of $25.81, for a total value of $150,549.73.

Rapport Therapeutics Price Performance

Shares of NASDAQ RAPP traded up $0.96 during trading on Thursday, hitting $29.64. 348,350 shares of the company were exchanged, compared to its average volume of 369,977. Rapport Therapeutics, Inc. has a 1 year low of $6.43 and a 1 year high of $42.27. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -10.94 and a beta of 1.63. The firm’s fifty day moving average price is $27.18 and its 200 day moving average price is $20.57.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.06. On average, research analysts forecast that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on RAPP shares. Citizens Jmp lifted their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. BTIG Research reissued a “buy” rating and issued a $47.00 target price on shares of Rapport Therapeutics in a report on Monday, December 8th. HC Wainwright raised their price target on Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group raised Rapport Therapeutics to a “strong-buy” rating in a research note on Friday, September 12th. Finally, Wall Street Zen raised shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.80.

Institutional Trading of Rapport Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP increased its position in Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock worth $45,949,000 after purchasing an additional 997,000 shares in the last quarter. Vestal Point Capital LP purchased a new position in Rapport Therapeutics in the 3rd quarter valued at about $28,215,000. Polar Capital Holdings Plc acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth about $27,887,000. Capital International Investors grew its holdings in shares of Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after buying an additional 800,000 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Rapport Therapeutics by 265.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company’s stock worth $26,500,000 after buying an additional 648,378 shares in the last quarter.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.